Core Viewpoint - CVS Group's CEO Richard Fairman is set to retire after seven years, with his departure attributed to personal reasons, while he will remain until a successor is appointed [2][3]. Company Leadership - Richard Fairman joined CVS Group in 2018 as CFO and became CEO in 2019, leading the company through significant strategic progress [2][3]. - The company is expected to attract a strong candidate for the CEO position due to its robust market position in the UK and Australia [3]. Market Context - CVS Group is part of the £6.7 billion ($8.89 billion) pet services market in the UK, which is undergoing regulatory changes requiring price transparency and capping prescription fees [4].

Group 1 - The company is experiencing technical difficulties during a webinar presentation, which has led to a restart of the session to ensure sound quality for participants [1][2] - The investor webinar series aims to provide insights into the company's innovative product platforms and the team driving its success [4]

Company Overview - IDEXX Laboratories, Inc. is a leader in veterinary diagnostics, software, and water testing solutions, based in Westbrook, Maine, with a market cap of $45.7 billion [1] - The company develops diagnostic instruments, test kits, software, and laboratory services for veterinarians, farmers, and laboratories to monitor animal health and detect diseases [1] Market Position - IDEXX is classified as a "large-cap stock" and is recognized as a market leader in veterinary diagnostics, benefiting from strong brand recognition and a large installed base of diagnostic instruments [2] - The company's solutions are utilized in over 175 countries, indicating a robust global presence [2] Stock Performance - Shares of IDEXX have decreased by 25.5% from their 52-week high of $769.98 and have dipped 18.5% over the past three months, underperforming the S&P 500 Index's decline of 2.9% [3] - Over the past six months, IDEXX shares are down 10.5%, while the S&P 500 has shown marginal returns [5] - Despite recent declines, IDEXX stock has increased by 41.2% over the past 52 weeks, outperforming the S&P 500's 20.1% increase during the same period [5] Recent Financial Performance - On February 2, IDEXX reported a strong fourth-quarter 2025 performance with revenue of $1.1 billion and adjusted earnings of $3.08 per share, both exceeding analyst expectations [6] - However, the gross margin of 60.3% fell short of the consensus forecast of 61% [6] Competitive Landscape - IDEXX has outperformed its main competitor, Zoetis Inc., which has seen a decline of 27.8% over the past 52 weeks and 22% over the past six months [7] - Analysts maintain a cautiously optimistic outlook for IDEXX, with a consensus rating of "Moderate Buy" and a mean price target of $773.58, representing a 34.8% premium to current levels [7]

Core Thesis - IDEXX Laboratories, Inc. is positioned for long-term growth in the pet healthcare sector, driven by increasing demand for veterinary diagnostics as pet owners seek advanced care for their animals [3][8]. Financial Performance - The company's diagnostic business is highly profitable, supported by recurring revenue and strong margins, contributing to a durable growth platform [4]. - IDEXX has consistently demonstrated robust financial performance, with earnings per share growth ranking in the top 10% of all companies over recent quarters and years [4]. - The share price has gained 60.4% over the past 52 weeks, placing it among the top 10% of stocks on a relative strength basis [6]. Market Trends - The aging cohort of pets born during the 2020 pandemic puppy boom adds a structural tailwind, as these animals will require more frequent veterinary visits and diagnostic testing [5]. - Pet owners are continuing to spend more per animal, further driving demand for veterinary services [5]. Investment Opportunity - IDEXX Laboratories offers an attractive opportunity for investors to capture both growth and consistent profitability in the pet healthcare sector [7]. - The company's outlook remains positive, making its shares a compelling buy for those seeking exposure to structural growth in veterinary diagnostics [8].

Core Insights - Zomedica will review its 2025 financial results and discuss opportunities in the equine veterinary market during an investor webinar on March 27, 2026 [1][2] - The equine industry contributes approximately $122 billion annually to the U.S. economy, highlighting a significant market opportunity for veterinary care [1] - The global equine population is estimated to exceed 60 million horses, indicating a substantial demand for veterinary services [1] Financial Performance - Zomedica reported an 8% revenue growth in 2024, reaching $27 million, and maintains a strong liquidity position of approximately $54.4 million as of September 30, 2025 [2] - The company aims to enhance revenue opportunities while moving towards sustained profitability [1][2] Market Opportunity - The equine veterinary services market represents a multi-billion-dollar opportunity, driven by increasing investment in sport horse medicine and advanced therapeutic technologies [1] - Annual care and training expenses for sport horses can range from $25,000 to over $100,000, depending on the discipline, further emphasizing the market potential [1] - The global veterinary diagnostics market is projected to exceed $10 billion by the end of the decade, with equine diagnostics being a specialized segment within this market [1] Product Portfolio - Zomedica's product offerings include the TRUFORMA® diagnostic platform, PulseVet® shock wave therapy, Assisi EquiLoop™ device, TRUVIEW® digital cytology, and VETIGEL® hemostatic gel, all designed to support veterinary practices [1][2] - The company focuses on addressing key clinical needs in equine medicine, particularly in endocrine diagnostics and metabolic disorders [1]

Core Insights - IDEXX Laboratories (IDXX) has experienced a significant stock price increase of 39.4% over the past year, outperforming the industry which saw a decline of 4.3% and the S&P 500 Composite's return of 23.1% [1] - The company holds a Zacks Rank 3 (Hold) and is benefiting from strong recurring revenues in its Companion Animal Group (CAG) Diagnostics, driven by improved net price realization and solid volume growth [1] Financial Performance - CAG Diagnostics' recurring revenues grew organically by 10% in Q4 2025, supported by volume growth and average global net price improvement [5][9] - The Zacks Consensus Estimate projects earnings per share (EPS) for 2026 and 2027 to increase by 11.2% and 12.4% year-over-year, reaching $14.55 and $16.36 respectively [13] - Revenues are expected to grow by 8.6% to $4.67 billion in 2026 and reach $5.09 billion in 2027, implying an 8.9% increase [13] Business Expansion and Innovation - IDEXX is expanding its international commercial footprint, enhancing clinic workflows through software solutions that promote greater utilization of diagnostics [2][10] - The company has launched several innovations, including the Cancer Dx diagnostic panel and the inVue Dx cellular analyzer, which are gaining commercial traction [6][10] - The software ecosystem, including practice information management systems (PIMS) and Vello tools, is crucial for improving clinic workflows and driving growth [11] Market Presence - IDEXX Laboratories operates in over 175 countries, focusing on innovation and customer service as key components of its long-term value creation strategy [4] - The company’s commercial strategies are tailored to regional dynamics, supported by strong Reference Laboratory networks [10] Challenges - The U.S. clinical visit growth is facing constraints due to staffing challenges at veterinary clinics and broader macroeconomic impacts on consumers [12]

Core Insights - CVS Group has reported continued progress in its interim results for the 6-month period ending December 2025, highlighting its commitment to providing the best possible care for animals [2] Group 1: Market Position and Growth - The company successfully transitioned from AIM to the Main Market on January 29, 2026, which is expected to enhance liquidity, diversify capital access, and improve company profile [2] - CVS has launched a new consumer-facing U.K. companion animal joint brand under CVS Vets, reflecting its commitment to care, value, and service [3] - The company is expanding its presence in Australia, having completed three acquisitions during the period and an additional two practice acquisitions in the second half of the year [3] Group 2: Investment and Regulatory Engagement - CVS continues to make disciplined capital investments to improve facilities, clinical equipment, and technology, aiming to drive long-term growth in shareholder value [4] - The company is engaging with DEFRA's consultation on the outdated Veterinary Surgeons Act from 1966, encouraging participation from CVS colleagues [4] - CVS is awaiting the final decision from the CMA, which is expected in the coming weeks [4]

CREATING CLARITY Raymond James 47th Annual Institutional Investors Conference Jay Mazelsky President and Chief Executive Officer IDEXX Laboratories, Inc. March 2, 2026 © 2026 IDEXX Laboratories, Inc. All rights reserved. Safe Harbor Disclaimer Please refer to additional footnotes in the Appendix. © 2026 IDEXX Laboratories, Inc. All rights reserved. 2 Innovation -driven Growth Forward-Looking Statements The following presentation contains forward-looking statements within the meaning of the Private Securitie ...

Core Insights - Zomedica's mission focuses on delivering innovative diagnostic and therapeutic technologies to enhance pet care and improve pet parent satisfaction [1][2] - The company aims to streamline workflow, increase cash flow, and boost profitability for veterinary practices [1] Company Objectives - The first pillar is to improve the quality of care for pets [2] - The second pillar emphasizes enhancing pet parent satisfaction, ensuring confidence in the care provided [2] - The third pillar focuses on improving veterinarians' daily workflow for smoother operations [2] - The fourth pillar is committed to positively impacting veterinarian cash flow, making offerings financially accessible [2] - The fifth pillar aims to increase veterinarian profitability, providing solutions that help clinics grow financially [2]

Core Insights - The rising costs of veterinary care are leading to a decline in vet visits, with a reported decrease of 2% to 3% in 2025, as pet owners are forced to skip visits due to budget constraints [1][1][1] - The veterinary industry has seen revenue growth of 2% in 2025, primarily driven by price increases of 5% to 6% year-over-year, rather than an increase in the number of visits [1][1][1] Industry Trends - The consolidation of veterinary clinics under corporate ownership is identified as a key factor behind the rising prices, with a significant portion of US veterinary practices now corporately owned [1][1][1] - Analysts from Bank of America indicate that while consolidation initially supported revenue and margin expansion, it has led to escalating prices that are pricing out pet owners from necessary care [1][1][1] Economic Implications - The decline in vet visits may signal broader economic challenges, as high inflation and a weak job market are squeezing household budgets, potentially leading to reduced consumer spending overall [1][1][1] - The trend of pet owners deferring or forgoing both elective and essential treatments could have long-term consequences for pet health and the veterinary industry [1][1][1]